LMAT · Lemaitre Vascular Inc
$78.51
-0.81 (-1.02%)
At close · Oct 8
Return incl. dividend (before tax)
Market Cap
$1.81B
Shares
22.87M
Volume · Oct 8
17.17K
Avg daily vol (3M)
329.99K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$79.31
Open$78.76
Day$78.58–80.47
52W close$78.80–117.39
Avg vol 30d263K
Short int1.7M · 7.4% float · 6.3d
Short vol71%
Last earningsAug 4, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 4 wks
filed Aug 5, 2026
call held Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$262.43M
Trailing 12 months
Net income (TTM)
$65.67M
Trailing 12 months
Revenue growth YoY
+9.6%
Year over year
Operating margin
29.5%
Trailing 12 months
P / E (TTM)
27.6
Trailing earnings · reciprocal yield 3.6%
FCF yield
4.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$26.62M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+7.2%
Year over year · more shares
Price change (1Y)
-9.6%
Trailing year
Short interest
7.4%
Latest settlement · 6.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 15.1 · calm
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−16%
below
Price vs 50-day avg
−4%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
1%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−29%
trailing
YTD return
−2%
this year
Relative strength
−40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $83 › 200d $95 — 200d above 50d
Institutional flow
Distributing
4 of 327 funds reported for Sep 30 · net -2.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.40% of float · ▲ +11.3% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
327 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+14%
Y/Y
Gross margin
72%
expanding
EPS growth
+31%
Y/Y
Free cash flow
$78.4M
Valuation
P/E 27.7
below peers
Buyback
$100.0M
authorized
Quant / Vol
risk profile
Volatility
45%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
2.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Full Year 2026
Sales
Initiated
$274.3M – $278.3M
prior FY $249.6M
midpoint +10.7% Y/Y
Gross Margin
Initiated
72.4%
Op. Income
Initiated
$75.3M – $78.2M
Op. Margin (Mid)
Initiated
28%
Q4 2026
Gross Margin
Initiated
72.6%
Op. Margin (Mid)
Initiated
29%
Prior guidance
period ended
· from the 8-K filed Aug 4, 2026
Gross Margin
· Q3 2026
72.2%
Op. Margin (Mid)
· Q3 2026
27%
Guided vs delivered
· last 8 settled
Sales
Q3 2024
guided $52.7M – $54.7M
$54.82M
Beat +2.1%
Sales
Full Year 2024
guided $216.8M – $220.8M
$219.86M
In line
Sales
Q2 2024 Guidance
guided $53.7M – $56.1M
$55.85M
In line
Sales
Q1 2024
guided $50.5M – $52.9M
$53.48M
Beat +3.4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−16%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $83 › 200d $95 — 200d above 50d
Institutional flow
Distributing
4 of 327 funds reported for Sep 30 · net -2.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.40% of float · ▲ +11.3% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
327 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $79
Now $79 · 1%
Range high $117
vs 200-day avg -16%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Direct-to-hospital net sales as percentage of total net sales | 95% | the three months ended June 30, 2026 filing | — |
| Effective income tax rate | 23.2% | the three months ended June 30, 2026 filing | — |
| Sales and marketing expenses as a percentage of net sales | 20% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LMAT
this stock
Lemaitre Vascular Inc
|
$1.81B | -2.2% | +13.5% | 27.7 | 7.4% |
|
ISRG
Intuitive Surgical Inc
|
$146.44B | -26.8% | +20.5% | 47.6 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.07B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$46.61B | -15.6% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.60B | -6.2% | +13.4% | 21.7 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LMAT | -4.0% | -0.2% | -29.0% | -4.0% | -2.2% |
| SPY | +1.9% | +1.9% | +10.8% | +1.9% | +14.0% |
| vs SPY | -5.9% | -2.1% | -39.7% | -5.9% | -16.2% |
Capital returns
Latest dividend
$0.25
/ share · ex Aug 20, 2026
Paid (TTM)
$0.95
/ share · 4 payouts
Dividend yield (TTM, derived)
1.20%
Buyback program
· as of Feb 19, 2026
Authorized
$100.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.